Radiation Therapy Do Little to Help Victims of Mesothelioma, but Photodynamic Therapy May Be a Promising Alternative
Oncologists and other cancer doctors decide what kind of treatment to pursue with every patient. There are numerous options. There is no standard treatment course for malignant mesothelioma victims. Mesotheliomas lack of agreed-upon treatment is due to low a treatment success rate, rareness, a high mortality rate and a small number of studies providing meaningful stats.
Mesothelioma patients have historically had a bleak outlook, but doctors have recently made progress. Traditional treatments for cancer are surgery (removing the tumor and surrounding tissue), radiation (killing the cancerous cells with radiation), and chemotherapy (poisoning the cancerous cells.) Each one of these methods have problems. Traditional radiation therapy has not worked well with mesothelioma patients. Researches, concerned about damage to healthy tissue, are looking for ways to aim radiation directly at tumors.
Surgery removes the mesothelial tissue around the tumor. The surgery is difficult and challenging, with unknown effects or benefits to patients. Most chemotherapy medication that work on other cancers typically do not work on mesothelioma, and different mixtures of these drugs have not been successful. Similar to radiation, focus in research is focusing on treating the physical location of the tumor with emphasis on the pleural cavity.
The high-mortality rate for mesothelioma patients means cutting-edge techniques for cancer are tried out. These include biologic therapy such as the agent interleukin 2 and anti-angiogenesis drugs such as thalidomide. Pemetrexed (Alimta) is a new drug that has shown results in extending life.
Considered by oncologists is where the tumor is located, what stage the mesothelioma is in, and the age and health of the patient. Two exotic ways of attacking mesothelioma are gene therapy and photodynamic therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.
